Breakfast Activity: Non-CE Satellite Symposium: A Treatment Option for Adult Patients With Locally Advanced or Metastatic Urothelial Cancer Merck & Co., Inc.
7:00 AM - 8:15 AM ET
Breakfast Activity/Non-CE Satellite Symposium: A Treatment Option for Adult Patients With Locally Advanced or Metastatic Urothelial Cancer Merck & Co., Inc.
7:00 AM - 8:15 AM ET
Breakfast Activity: Non-CE Satellite Symposium: Reducing access barriers: New FDA label updates on cell therapy post-treatment monitoring requirements Bristol Myers Squibb
7:00 AM - 8:15 AM ET
Breakfast Activity/Non-CE Satellite Symposium: Reducing access barriers: New FDA label updates on cell therapy post-treatment monitoring requirements Bristol Myers Squibb
7:00 AM - 8:15 AM ET
Breakfast Activity: Non-CE Satellite Symposium: Supporting Patients With HR+/HER2- mBC Throughout Their Treatment Journey Pfizer, Inc.
7:00 AM - 8:15 AM ET
Breakfast Activity/Non-CE Satellite Symposium: Supporting Patients With HR+/HER2- mBC Throughout Their Treatment Journey Pfizer, Inc.
Lunch Activity: Non-CE Satellite Symposium: A 2L Treatment Option for HR+/HER2− aBC or mBC With PIK3CA, AKT1, or PTEN Alterations Following Progression on or After ET ± CDK4/6i AstraZeneca
1:00 PM - 2:20 PM ET
Lunch Activity/Non-CE Satellite Symposium: A 2L Treatment Option for HR+/HER2− aBC or mBC With PIK3CA, AKT1, or PTEN Alterations Following Progression on or After ET ± CDK4/6i AstraZeneca
1:00 PM - 2:20 PM ET
Lunch Activity: Non-CE Satellite Symposium: A Treatment Option for Adults with Certain R/R DLBCL After ≥2 Prior Lines of Systemic Therapy Pfizer, Inc.
1:00 PM - 2:20 PM ET
Lunch Activity/Non-CE Satellite Symposium: A Treatment Option for Adults with Certain R/R DLBCL After ≥2 Prior Lines of Systemic Therapy Pfizer, Inc.
1:00 PM - 2:20 PM ET
Lunch Activity: Non-CE Satellite Symposium: Addressing Real-World Clinical Evidence in Polycythemia Vera and Myelofibrosis: Subtitle: A Case-Based Discussion on Clinical Decision Making Incyte Corporation
1:00 PM - 2:20 PM ET
Lunch Activity/Non-CE Satellite Symposium: Addressing Real-World Clinical Evidence in Polycythemia Vera and Myelofibrosis: Subtitle: A Case-Based Discussion on Clinical Decision Making Incyte Corporation
1:00 PM - 2:20 PM ET
Lunch Activity: Non-CE Satellite Symposium: Alternative Routes of Administration: Advancing Oncology Care with Subcutaneous Immunotherapy Bristol Myers Squibb
1:00 PM - 2:20 PM ET
Lunch Activity/Non-CE Satellite Symposium: Alternative Routes of Administration: Advancing Oncology Care with Subcutaneous Immunotherapy Bristol Myers Squibb
Independent CE Satellite Symposium: Relapsed/Refractory Multiple Myeloma: Evidence-Based Guidelines and Essential Strategies for Optimized Treatment Selection and Sequencing
6:00 PM - 7:00 PM ET
Independent CE Satellite Symposium: Relapsed/Refractory Multiple Myeloma: Evidence-Based Guidelines and Essential Strategies for Optimized Treatment Selection and Sequencing
CE/CME: 0.75
7:30 PM - 9:00 PM ET
Independent CE Dinner Satellite Symposium: Managing HER2 and TROP2 ADC Adverse Events: Advanced Practice Providers Case Discussions Highlighting the Critical Roles in Patient Care
7:30 PM - 9:00 PM ET
Independent CE Dinner Satellite Symposium: Managing HER2 and TROP2 ADC Adverse Events: Advanced Practice Providers Case Discussions Highlighting the Critical Roles in Patient Care
